SMALL CELL LUNG CANCER (SCLC)

This study tests whether adding an experimental drug called obrixtamig to standard chemotherapy and immunotherapy helps people with advanced small cell lung cancer live longer. About 670 adults with extensive-stage disease will be randomly assigned to receive either the new combi…

This study tests a new drug, peluntamig, in people with advanced neuroendocrine cancers (like small cell lung cancer) that have a specific marker called DLL3. The trial has two parts: first finding the safest dose, then testing it alone or with chemotherapy. About 203 participant…

This study looks at how safe and effective the drug adebrelimab is for people with advanced small cell lung cancer. Researchers will follow 500 patients in real-world clinics to track side effects and survival. The goal is to see if this treatment helps control the disease better…

This study tests an experimental drug called VMD-928, taken as a pill, alone or with pembrolizumab (an immunotherapy) in adults with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find safe doses and see if the drug shrinks t…

This study tests a new drug that delivers radiation directly to cancer cells with a specific marker called DLL3. It is for adults with small cell lung cancer or other solid tumors that have this marker and have not responded to standard treatments. The goal is to see if the drug …

This study tests a new medicine called PF-08634404 combined with chemotherapy for adults with extensive-stage small cell lung cancer, a fast-growing cancer that has spread. About 550 people who haven't had prior treatment for this stage will join. The goal is to see if the new co…

This early-stage study tests a new drug called EXS74539 in about 40 adults with certain solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to find a safe dose and check for side effects. Researchers will also watch for any signs that the drug sh…

This study tests an experimental drug called CP-383 in people with advanced solid tumors that have not responded to standard treatments. The main goals are to find the safest dose and see if the drug can shrink or slow cancer growth. About 150 participants will take CP-383 daily …

This early-phase study tests a new drug called 177Lu-RAD204 in people with advanced solid tumors (like lung, breast, or skin cancer) that have not responded to other treatments. The drug delivers a small amount of radiation directly to cancer cells by targeting a protein called P…

This study tests a new treatment using specially designed natural killer (NK) cells to attack small cell lung cancer that has come back or not responded to standard therapy. About 60 adults aged 18-75 with advanced disease will receive these cells through an IV. The goal is to fi…

This study is observing how lung cancer patients fare when treated with the immunotherapy drug Tislelizumab in everyday clinics, not just in controlled trials. Researchers will track survival, treatment patterns, side effects, and quality of life in 240 participants across German…